title: Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.
abstract: The effects of soluble TNF-alpha receptor, etanercept, on bone metabolism were investigated in patients with rheumatoid arthritis (RA). Thirty RA patients were administered etanercept once or twice a week for more than 6 months. We evaluated clinical and laboratory parameters and measured urinary excretion levels of pyridinoline (PYD), deoxypyridinoline (DPD), cross-linked N-telopeptides of type I collagen (NTX), and serum levels of bone alkaline phosphatase (BAP), osteoprotegerin (OPG), and soluble receptor activator of NFkappaB ligand (sRANKL) at the baseline and at 3 and 6 months after initial treatment with etanercept. Etanercept treatment resulted in an improvement of symptoms due to RA and in a reduction of urinary excretion levels of PYD and DPD as well as serum sRANKL levels, with a significant difference at 6 months, and an increase of serum BAP levels at 3 and 6 months after the initial treatment with etanercept. Urinary NTX and serum OPG levels did not show a significant change at 3 and 6 months after the initial treatment, but serum OPG levels did show a reverse correlation with serum CRP levels, suggesting that the regulation of inflammation in RA may result in an induction of OPG production. Etanercept may have the ability to reduce the levels of bone resorption markers and to increase the levels of a bone formation marker while reducing sRANKL formation in RA patients.
authors.affiliation: Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. Tsukatonpipi@nifty.com
authors.forename: Kageyama
authors.initials: K
authors.lastname: Yasunori
authors.forename: Takahashi
authors.initials: T
authors.lastname: Masaaki
authors.forename: Nagafusa
authors.initials: N
authors.lastname: Tetsuyuki
authors.forename: Kobayashi
authors.initials: K
authors.lastname: Hayato
authors.forename: Nagano
authors.initials: N
authors.lastname: Akira
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D000596:Amino Acids / Q000652:urine*; D001172:Arthritis, Rheumatoid / Q000378:metabolism*; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001842:Bone and Bones / Q000378:metabolism; D024042:Collagen Type I / Q000652:urine; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D053244:Osteoprotegerin / Q000097:blood; D010455:Peptides / Q000652:urine; D053245:RANK Ligand / Q000097:blood*; D018124:Receptors, Tumor Necrosis Factor
chemical_list: D000596:Amino Acids; D015415:Biomarkers; D024042:Collagen Type I; D007074:Immunoglobulin G; D053244:Osteoprotegerin; D010455:Peptides; D053245:RANK Ligand; D018124:Receptors, Tumor Necrosis Factor; C505688:TNFSF11 protein, human; C052929:collagen type I trimeric cross-linked peptide; C015484:pyridinoline; C036020:deoxypyridinoline; D000469:Alkaline Phosphatase; D000068800:Etanercept